http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유전자 재조합 B 형 간염 바이러스 표면 항원 , CJC-50100 의 일반약리작용
정성학(Seong Hak Jeong),최재묵(Jae Mook Choi),이남중(Nam Jung Lee),전형수(Hyung Soo Jeon),김연희(Yon Hee Kim),김재승(Jae Seung Kim),하석훈(Suk Hoon Ha),김영훈(Young Hoon Kim),이나경(Na Gyung Lee),김제학(Je Hak Kim),박완제(Wan Je Park 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33∼33.3 ㎍/㎏ i.m. for mice and rats and 3.3∼9.9 ㎍/㎏ i.v. for dogs. The concentrations of 0.002∼0.02 ㎍/mlwere used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 ㎍/man/60 kg.